Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219817 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
A Phase 2 study, sponsored by Helsinn Therapeutics (U.S.).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00219817 is a Phase 2 study that has completed, run by Helsinn Therapeutics (U.S.). The registered enrollment target is 80 participants.
The verdict
NCT00219817, a Phase 2 study, has completed, sponsored by Helsinn Therapeutics (U.S.).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.
Interventions
- DRUG RC-1291 HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219817
The ClinicalTrials.gov registry entry for NCT00219817 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helsinn Therapeutics (U.S.), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RC-1291 HCl is the first listed.
NCT00219817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00219817 about?
NCT00219817 is a clinical study titled "Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss". Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone relea...
What is the current status of trial NCT00219817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-06. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00219817?
The interventions under investigation include: RC-1291 HCl (DRUG).
Who is sponsoring clinical trial NCT00219817?
This trial is sponsored by Helsinn Therapeutics (U.S.), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.